Paul D. Hansen

Complications nearly double the cost of care after pancreaticoduodenectomy

BACKGROUNDnDespite considerable data focused on the morbidity of pancreaticoduodenectomy (PD), the financial impact of complications has been infrequently analyzed. This study evaluates the impact of the most common complications associated with PD on the cost of care. Additionally, we identified cost centers that were significantly affected by complications.nnnMETHODSnA retrospective analysis of a prospective database in a network of community-based teaching hospitals was performed. All patients (n = 145) who underwent PD were included for years 2005 to 2009. Of these, 144 had complete in-hospital cost data. Complications were assessed and classified into major and minor categories according to Dindo et al. Forty-nine cost centers were analyzed for their association with the cost of complications. Univariate and multivariate linear regression analyses were performed. Significance was reported for P < .05.nnnRESULTSnThe median cost for PD was

Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases

30,937. Patients with major complications had significantly higher median cost compared with those without (

Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience.

56,224 vs

Training in Minimally Invasive Pancreatic Resections: A paradigm shift away from "See one, Do one, Teach one"

29,038; P < .001). Independent predictors of increased cost included reoperation; sepsis; pancreatic fistula; bile leak; delayed gastric emptying; and pulmonary, renal, and thromboembolic complications. Cost center analysis showed significant added charges for patients with major complications for blood bank (

Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors

1,018), clinical laboratory (

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma

3,731), a computed tomography scan (

Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base

4,742), diagnostic imaging (

Outcomes Following Laparoscopic Choledochoduodenostomy in the Management of Benign Biliary Obstruction

697), intensive care unit (

Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs

4,986), pharmacy (

Evaluation of a minimally invasive image-guided surgery system for hepatic ablation procedures.

33,850) and respiratory therapy (